000			04181nam a2200337 i 4500
999			_c399376 _d399376
001			399376
003			ES-MaUEC
005			20240418145951.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			231031s2023 sz | fo |||| 0|eng d
020			_a9783031390203
024	7		_a10.1007/978-3-031-39020-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC111 _b2023 EB
245	0	0	_aNanomedicines for the Prevention and Treatment of Infectious Diseases _cedited by Vandana B. Patravale, Abhijit A. Date, Anil B. Jindal
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-738X _v56
505	0		_aNanocarriers for delivery of peptide antibiotics -- NANOMEDICINES FOR THE PULMONARY DELIVERY OF ANTIBIOTICS -- Inhalable nanomedicines for the treatment of pulmonary aspergillosis -- Nanomedicines for the treatment of systemic candidiasis -- Nanomedicine for the treatment of vaginal candidiasis -- Nanomedicines for the treatment of veterinary parasitic infections -- Role of Nanotechnology Against Malaria: Current Perspectives and Strategies -- NANOMEDICINES FOR THE TREATMENT OF TRYPANOSOMIASIS -- Nanomedicines to improve oral delivery of antiretroviral drugs -- Nano-Adjuvants -- Nanoscale Vaccines for Influenza -- Nano-scale vaccines for the prevention of hepatitis B virus infection -- Nanoscale Vaccines for the Prevention of COVID-19.
520			_aThe COVID-19 pandemic has altered the world and reiterated the perpetual need for the development of effective strategies for the prevention and treatment of infectious diseases. While globally prevalent infectious diseases receive extensive attention in terms of drug development and delivery, the neglected and/or emerging infectious diseases that affect developing countries are often overlooked. From the commercialization of AmBisome® to the emergency authorization of mRNA-based vaccines, nanotechnology has played a vital role in the prevention and treatment of infectious diseases. More importantly, nanotechnology has enabled the effective utilization of existing armamentarium against infectious diseases leading to improved therapeutic outcomes with a concomitant reduction in the side effects associated with anti-infective agents. In particular, nanotechnology can bring about a paradigm shift in the management of neglected and emerging infectious diseases and may compensate for the lack of drug discovery efforts. This book addresses an unmet need in pharmaceutical and medical education. This book provides a comprehensive and up-to-date overview of the latest advancements in nanomedicine, which show great potential for preventing and treating infectious diseases. Covering a wide range of topics, it explores various formulation strategies for combating microbial, fungal, parasitic, and viral infections. The book emphasizes the advantages of nano-scale vaccines over traditional ones and discusses their production. It also examines feasible treatment approaches for diseases like malaria, trypanosomiasis, candidiasis, Hepatitis B, HIV, and the ongoing COVID-19 pandemic. Additionally, it highlights the role of nano-adjuvants in vaccine development, as well as the use of peptide antibiotics and pulmonary delivery of drugs, which open up new possibilities in fighting infectious diseases. Furthermore, the book explores the critical role of nanomedicine in addressing veterinary parasitic infections. The emergence of nanotechnology has led to novel strategies for diagnosing, treating, and preventing parasitic infections in animals.
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9138404 _aEnfermedades infecciosas
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-39020-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b04/2024 _dz _eb _zSI